

Qualcomm opened a software development and engineering center, moving from a 2,225 sf to an 11,500 sf center in January 2009. The San Diego based company designs chips used in cell phone products and its Champaign office will develop chip integrating software.

Singleton Law Firm, P.C. moved into new 2,225 sf office at 2001 S. First St. in January 2009. Singleton Law firm has worked with dozens of firms in the Research Park and specializes in company formation, intellectual property, and corporate transactions.

Integrated Data Security (IDS) moved into a new data center space at 1800 S. Oak St. (Gateway Building) in December 2008. IDS provides services to manage the growth of business' information while maintaining the integrity and security of its most sensitive and valuable digital assets.

Strata Decision Technology renewed its lease for two years, through 2011. Strata sells software for strategic financial planning, budgeting, and decision making with a focus on hospitals and healthcare systems.

Powerworld Corporation renewed its lease for an additional five years, through 2014. Powerworld provides electrical power systems analysis and visualization software that is sold to power companies globally.

Illini Computing, Inc. signed a lease renewal amendment to extend through February 2010 in the Gateway Building. Illini Computing is a full-service technology consulting company offering custom software development applications that work to streamline business operations by integrating products currently used by businesses.

University of Illinois

TED Update

Report to the Technology and Economic Development Committee

FY09
Q2

Innovation Challenge Technical Assistance Grant

The Office of the Vice President for Technology and Economic Development is partnering with the Illinois Department of Commerce and Economic Opportunity (DCEO) to administer a new program that provides qualified Illinois small businesses and entrepreneurs with consultant services to assist in the preparation of Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) grant applications.

The Innovation Challenge Technical Assistance Grant supplies access to consultants who will provide services which include:

- Identifying funding opportunities, and matching a company's strengths and capabilities with the right Federal agency solicitation.
- Assistance with grant writing, review, and critique.
- Assistance with marketing and networking to develop relationships with Federal labs and other technology partners.

Recipients gain up to \$5,000 of consultant time, which translates to approximately 30 hours.

Illinois-based companies as well as entrepreneurs who have not yet incorporated can apply for this grant. More information and the online application form are available at:

www.innovations.uillinois.edu



this issue

CDG Therapeutics, Innovation Challenge Grant **P.1**

New Technologies, OTM Licensed Startups **P.2**

IllinoisVENTURES **P.3**

Offices of Technology Management,


Research Park at the University of Illinois **P.4**

CDG Therapeutics, Inc.

CDG Therapeutics, Inc. founded by **Ananda M. Chakrabarty Ph.D.** and **Tapas K. Das Gupta, M.D., Ph.D., D. Sc.**, two faculty members in the University of Illinois, Chicago College of Medicine, is engaged in the development of proprietary peptides (p28) derived from pathogenic and nonpathogenic bacteria and green plants. These peptides possess a unique ability to preferentially enter cancer cells and induce cell cycle arrest and ultimately cell death.

CDG Therapeutics currently has 15 full and part time employees including 4 Ph.D. scientists across a multi-disciplinary spectrum of expertise which includes pharmacology, cell biology, microbiology, molecular biology and experimental pathology. Several CDG employees and Directors have previous corporate (pharmaceutical) and regulatory experience as well as sustained funding from the NIH. CDG Therapeutics is the sole licensee of intellectual property that includes four patents issued to UIC on the founders' core technology and improvements.

Recent company milestones include: support from a National Cancer Institute Division of Cancer Treatment RAID (Rapid Access to Investigational Drugs) that conducted all pharmacokinetic, metabolism and stability studies on p28; as well as packaging of the sterile product for patient use; Institutional Review Board (IRB) approval; a Phase I (drug safety) trial of p28 in patients with advanced cancer; and award of an IND (Initial New Drug Application) by the FDA to CDG Therapeutics, Inc.



MAPAS software, a tool for predicting membrane-contacting protein surfaces, was used to identify and define what part of the protein surface of azurin, a protein secreted by the bacterium *Pseudomonas aeruginosa*, contacts and preferentially penetrates a cancer cell. p28, CDG Therapeutics lead anti-cancer compound, is responsible for preferential penetration of a cancer cell and significant anti-cancer activity.

OTM: FY09 Year to Date and FY08 End of Year Results

	FY 2008 Total			FY 2009 Year to Date		
	Chicago	Urbana	Total	Chicago	Urbana	Total
Disclosures Received	120	244	364	59	100	159
U. S. Patents Filed	184	181	365	93	77	170
U. S. Patents Issued	16	38	54	8	15	23
Licenses & Options	18	43	61	8	17	25
Licenses to Start-Ups	5	6	11	1	4	5
*Royalties Earned	\$4.477M	\$4.235M	\$8.712M	\$5.491M	\$1.820M	\$7.311M
Patent Cost Reimbursement	\$0.266M	\$0.899M	\$1.165M	\$0.179M	\$0.615M	\$0.794M
Non-University Share	\$0.577M	\$0.178M	\$0.755M	\$0.339M	-	\$0.339M
**Net for Distribution	\$3.637M	\$2.816M	\$6.453M	\$4.455M	\$1.199M	\$5.654M

*In FY08 \$1,481,855 was distributed to inventors, and \$2,635,673 was returned to the campuses and campus units.

**FY09 year to date, \$1,770,409.01 was distributed to inventors, and \$2,076,161.70 was returned to the campuses and campus units.

OTM Licensed Start-Ups FY09 YTD

Eden Park Illumination

Eden Park Illumination, co-founded by Professors **J. Gary Eden** and **Sung-Jin Park**, of the Laboratory for Optical Physics and Engineering, is commercializing Microcavity Plasma (or "microplasma") lighting technology. This platform technology is a new light source innovation, and offers unique advantages over both traditional light sources, such as incandescent and fluorescent, and the newer lighting technologies such as light emitting diodes ("LED") and organic light emitting diodes ("OLED"). www.edenpark.com

Cazoodle, Inc.

Cazoodle Inc., co-founded by Prof. **Kevin C. Chang** and his research team in the Department of Computer Science, provides software and internet services for Web search, integration, and mining, with a central objective to "deepen" search on the Web--to access the vast amount of data beyond the reach of current search engines. The company is located in EnterpriseWorks. www.cazoodle.com

Surf Canyon

Surf Canyon, a start-up located in Oakland, California, has licensed internet search technology co-developed by computer science professor **Cheng-Xiang Zhai** and Surf Canyon's CEO. www.surfcanyon.com

Cbana Laboratories

Cbana Laboratories is commercializing adsorbents and microfluidic and microanalytical devices originally developed in the laboratories of Professors **Rich Masel** and **Mark Shannon** for the capture and analysis of pollutants, drugs and other dangerous materials. www.cbana.com

Bringing a new apple to market

The Office of Technology Management is working with **Dr. Schuyler Korban**, from the Department of Natural Resources and Environmental Sciences, to commercialize the new **WineCrisp™** apple. The WineCrisp™ carries the Vf gene for scab resistance, and took more than 20 years to develop through classical breeding techniques.

Apple scab is a major concern at orchards. The typical Illinois grower sprays their trees 15 to 20 times a year to fight scab. Not having to spray lowers costs and is better for the environment. Another important trait of the WineCrisp™ is its ability to keep well in cold storage.

WineCrisp™ was developed as part of the Purdue-Rutgers-Illinois Cooperative Breeding Program, which has released more than 25 disease-resistant apple variations. The University of Illinois is handling licensing and patenting. A U.S. patent is pending and the Office of Technology Management is working with interested nurseries and orchards across the United States and internationally.



Web Publishing Accessibility Wizard makes documents available to people with disabilities

The Web Publishing Accessibility Wizard for Microsoft® Office provides an easy user interface and automation to simplify the task of converting PowerPoint presentations to disabled-accessible HTML. The Wizard enables easy compliance with regulations in Section 508 of the Rehabilitation Act, which establishes requirements for electronic and information technology developed or used by the Federal government.

Now licensed by **LK4 Technology Corporation**, the Web Publishing Accessibility Wizard was previously available on the Office of Technology Management's ecommerce webstore, where it was distributed to more than 5,000 users.

Small Molecule Synthesis Will Promote New Discoveries in Science and Medicine

The OTM is working with Sigma-Aldrich to enable worldwide commercial access to a collection of powerful new building blocks for organic synthesis. The license enables the complementary strengths of a leading research university and a leading chemical company to be maximally harnessed for the benefit of the worldwide research community

Professor **Martin Burke** and coworkers in the Department of Chemistry at the University of Illinois at Urbana-Champaign recently reported the discovery of a new platform for making organic molecules that involves stitching together a collection of modified boronic acid building blocks using only a single chemical reaction in an iterative manner. This approach has the potential to make the preparation of new organic compounds significantly more efficient and flexible.

These building blocks are also remarkably stable to storage under air and can be easily purified by standard chromatographic and/or crystallization techniques.

Collectively, these features suggest the potential for a wide range of applications spanning the chemical, pharmaceutical and petrochemical industries. Potential applications include more rapid preparation of new drug candidates for screening, more efficient and environmentally friendly large-scale synthesis of established drugs, simple and flexible preparation of naturally-occurring bioactive molecules, and more effective synthesis of new materials.

The portfolio is licensed exclusively to Aldrich for small amounts to be used in research, and the Office of Technology Management is also in talks with major chemical manufacturers for the rights to synthesize compounds on a large scale.

HemaQuest Pharmaceuticals Licenses Multi-Application Technology

In October of 2008, HemaQuest Pharmaceuticals entered into an exclusive technology license agreement with the University of Illinois at Chicago (UIC) to develop and commercialize sickle cell anemia, beta thalassemia, and cancer therapeutics around a multi-application technology invented by UIC scientists **Dr.'s Joseph Desimone** and **Yogen Sauntharajah**. This UIC technology is a novel formulation that eliminates the need for the injection of Decitabine by making it orally absorbable. Decitabine is a FDA approved drug for the treatment of a blood disorder named myelodysplastic syndrome, or pre-leukemia. In addition to its new therapeutic uses, this novel formulation decreases inter-individual variability, lowers required dosage without hampering effects, and improves the ability to overcome cancer cell resistance.

HemaQuest is a well-funded, recently established company that specializes in anemia and other blood disorder therapeutics. In addition to the UIC technology, Hemaquest has three to four other technologies in its pipeline that it is planning to commercialize. Hemaquest showed interest in the UIC technology after UIC scientists demonstrated the effectiveness of their formulation through relevant clinical studies and it is planning to initiate its own clinical studies soon after fine-tuning the compound's formulation. Additionally, HemaQuest has generously offered to sponsor Dr. Desimone's lab for further developments. With an estimated market size of \$5B and the commercialization strength of HemaQuest, this technology is expected to bring the University substantial returns when marketed.

Startups Garner Venture Funding

The current economic downturn has severely constrained the availability of venture funding for many emerging companies. But not so for four university related startups—all members of the IllinoisVENTURES portfolio—obtained significant new rounds of venture financing in the latest quarter. The additional funding is a testimony to the resiliency of these companies and their future potential.

Chromatin – completed a \$9M raise to launch bioenergy feedstock strategy.

Tetravitae Biosciences - completed \$6M funding.

Riverglass – Obtained \$4M in combined equity and venture debt round.

Fluensee – obtained \$1.5 Venture debt round.

IllinoisVENTURES, LLC

Total funding to date now approximately \$26 million with over 10:1 "leverage" of third-party investor and grant funding.

Summary	Total (Since January 2003)
Clients:	Engaged Consultatively Receiving Developmental Funding
	1,026 64
Funding:	Dollars Approved Dollars Funded
	\$26,709,000 \$26,009,000
Additional 3 rd Party Co-Investments, Grant Funding	
	\$261,000,000